ASCO 2025: Zanidatamab plus chemotherapy shows strong first-line efficacy in HER2-positive gastro-oesophageal adenocarcinoma
A phase 2 trial reports high response rates and durable outcomes in treatment-naive patients, presented…
Browsing: Featured Events
ASCO GU 2025: Mobile prostate cancer screening clinic can help address barriers to serving high-risk communities
A new study from the UK found that a mobile prostate cancer screening clinic called…
SABCS 2024: Camizestrant plus ribociclib improves PFS and responses in ER+/HER2– breast cancer
Results from the multicentre, first-in-human phase 1 SERENA-1 trial (NCT03616587) presented at the 2024 San…
Let’s Talk About Sex
Are you talking to your patients about sex enough? Research suggests that most healthcare professionals aren’t having these conversations as often as patients would like.
Circadian clock and gut microbiome changes linked to colon cancer progression
Research from the University of California, Irvine, USA, has revealed how disruption of the circadian…
WCLC 2024: NeoCOAST-2 Data shows combination of Durvalumab with novel agents increases pathological responses in resectable NSCLC — Data builds on AEGEAN study research
Phase 2 results from the NeoCOAST-2 study demonstrated that the combination of durvalumab with Dato-DXd…
WCLC 2024: NeoCOAST-2 Data shows combination of durvalumab with novel agents increases pathological responses in resectable NSCLC
Phase 2 results from the NeoCOAST-2 study demonstrated that the combination of durvalumab with Dato-DXd…
WCLC 2024: PanCan nodule management protocol more effective than LungRADSv1.1 method
New data presented today reveals that the PanCan nodule management protocol demonstrates superior performance in…
Preview: World Cancer Congress in Geneva
UICC’s flagship event is taking place 17-19 September in Geneva, Switzerland. It is expected to…
ASCO 2024: Promising results from the first clinical trial of an innovative next-generation antibody in patients with advanced solid tumours, especially in melanoma
Initial data from the first phase 1 trial of the bispecific antibody FS222 demonstrate that…